JP2022529518A5 - - Google Patents
Info
- Publication number
- JP2022529518A5 JP2022529518A5 JP2021563139A JP2021563139A JP2022529518A5 JP 2022529518 A5 JP2022529518 A5 JP 2022529518A5 JP 2021563139 A JP2021563139 A JP 2021563139A JP 2021563139 A JP2021563139 A JP 2021563139A JP 2022529518 A5 JP2022529518 A5 JP 2022529518A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- groups
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838696P | 2019-04-25 | 2019-04-25 | |
| US62/838,696 | 2019-04-25 | ||
| PCT/US2020/029849 WO2020219904A1 (en) | 2019-04-25 | 2020-04-24 | Heterocyclic inhibitors of tyrosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529518A JP2022529518A (ja) | 2022-06-22 |
| JP2022529518A5 true JP2022529518A5 (enExample) | 2023-05-02 |
| JP7601788B2 JP7601788B2 (ja) | 2024-12-17 |
Family
ID=72941423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563139A Active JP7601788B2 (ja) | 2019-04-25 | 2020-04-24 | チロシンキナーゼの複素環式阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11365189B2 (enExample) |
| EP (1) | EP3962908A4 (enExample) |
| JP (1) | JP7601788B2 (enExample) |
| CN (2) | CN118852118A (enExample) |
| AU (1) | AU2020261423B2 (enExample) |
| CA (1) | CA3137901A1 (enExample) |
| WO (1) | WO2020219904A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| CA3137901A1 (en) | 2019-04-25 | 2020-10-29 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of tyrosine kinase |
| WO2021127397A1 (en) * | 2019-12-19 | 2021-06-24 | Black Diamond Therapeutics, Inc. | Nitrogen heterocyclic compounds and methods of use |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| US20240246940A1 (en) * | 2021-04-22 | 2024-07-25 | Voronoi Inc. | Heteroaryl derivative compound and use thereof |
| WO2022266426A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof |
| WO2022266425A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 3-cyano-quinoline derivatives and uses thereof |
| AR126849A1 (es) * | 2021-08-24 | 2023-11-22 | Arthrosi Therapeutics Inc | Compuestos de quinazolina para tratamiento de enfermedad |
| CN115894486B (zh) * | 2021-09-30 | 2024-02-09 | 北京赛特明强医药科技有限公司 | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492536B1 (de) * | 2002-03-30 | 2012-05-09 | Boehringer Ingelheim Pharma GmbH & Co.KG | 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| KR101217526B1 (ko) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| CN104513229A (zh) | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| CN106068262B (zh) | 2014-04-11 | 2019-10-29 | 海思科医药集团股份有限公司 | 喹唑啉衍生物及其制备方法和在医药上的应用 |
| ES2775614T3 (es) | 2015-03-20 | 2020-07-27 | Chai Tai Tianqing Pharmaceutical Group Co Ltd | Sales de derivado de quinazolina y método de preparación de las mismas |
| CN113149960A (zh) | 2016-08-25 | 2021-07-23 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物的盐的晶体 |
| US11427559B2 (en) * | 2018-02-20 | 2022-08-30 | Teligene Ltd. | Substituted quinolines useful as kinase inhibitors |
| CA3137901A1 (en) | 2019-04-25 | 2020-10-29 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of tyrosine kinase |
-
2020
- 2020-04-24 CA CA3137901A patent/CA3137901A1/en active Pending
- 2020-04-24 CN CN202410871766.0A patent/CN118852118A/zh active Pending
- 2020-04-24 JP JP2021563139A patent/JP7601788B2/ja active Active
- 2020-04-24 US US16/858,116 patent/US11365189B2/en active Active
- 2020-04-24 CN CN202080045535.4A patent/CN114026083B/zh active Active
- 2020-04-24 EP EP20796402.4A patent/EP3962908A4/en active Pending
- 2020-04-24 WO PCT/US2020/029849 patent/WO2020219904A1/en not_active Ceased
- 2020-04-24 AU AU2020261423A patent/AU2020261423B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025525406A5 (enExample) | ||
| JP2024100974A5 (enExample) | ||
| JP2021514001A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| JP2021523200A5 (enExample) | ||
| JP2022551185A5 (enExample) | ||
| JP2023075344A5 (enExample) | ||
| JP2021522280A5 (enExample) | ||
| JP2012529535A5 (enExample) | ||
| JP2008504240A5 (enExample) | ||
| JP2012500260A5 (enExample) | ||
| RU2017121906A (ru) | Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии | |
| JP2019034943A5 (enExample) | ||
| CN111094242A (zh) | 用于治疗与nlrp活性相关的病症的化合物和组合物 | |
| JP2023520925A5 (enExample) | ||
| JP2012526728A5 (enExample) | ||
| JP2024539946A5 (enExample) | ||
| JP2020535124A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| CA2556669A1 (en) | Hepatitis c inhibitor peptide analogs | |
| JP2020502047A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2023164918A5 (enExample) | ||
| JP2022548247A5 (enExample) | ||
| JP2024545787A5 (enExample) |